Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 10/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 10/20 | 0.38 |
| ▸ | ITGB7 | P26010 | 8/20 | 0.38 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.36 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.36 |
| ▸ | ITGAL | P20701 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 8/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30901315 | 1.00 | ITGB1 (0.38) | ITGB1ITGA4ITGB7ITGB2ICAM1 | |
| SCHEMBL21979254 | 1.00 | ITGB1 (0.38) | ITGB1ITGA4ITGB7ITGB2ICAM1 | |
| SCHEMBL21979249 | 1.00 | ITGB1 (0.38) | ITGB1ITGA4ITGB7ITGB2ICAM1 | |
| SCHEMBL29671150 | 0.96 | CNR2 (0.39) | ITGB1ITGA4ITGB7CNR2CNR1 | |
| SCHEMBL22035239 | 0.96 | CNR2 (0.39) | ITGB1ITGA4ITGB7CNR2CNR1 | |
| SCHEMBL21978767 | 0.92 | ITGA4 (0.41) | ITGB1ITGA4ITGB7ITGB2ICAM1 | |
| SCHEMBL21978768 | 0.92 | ITGA4 (0.41) | ITGB1ITGA4ITGB7ITGB2ICAM1 | |
| SCHEMBL21978771 | 0.92 | ITGA4 (0.41) | ITGB1ITGA4ITGB7ITGB2ICAM1 | |
| SCHEMBL21957435 | 0.92 | ITGB1 (0.35) | ITGB1ITGA4ITGB7ITGB2ICAM1 | |
| SCHEMBL21957433 | 0.92 | ITGB1 (0.35) | ITGB1ITGA4ITGB7ITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3873605-B1 | COMPOUNDS FOR INHIBITION OF ALPHA4BETA7 INTEGRIN | GILEAD SCIENCES INC (US) | 2024-10-23 | — | — | EP | disclosed |
| CN-112969504-B | Compounds for inhibiting alpha 4 beta 7 integrin | 吉利德科学公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | GILEAD SCIENCES, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3873605-A1 | COMPOUNDS FOR INHIBITION OF ALPHA4BETA7 INTEGRIN | GILEAD SCIENCES, INC. (US) | 2021-09-08 | — | — | EP | disclosed |
| CN-112969504-A | Compounds for inhibiting alpha 4 beta 7 integrins | 吉利德科学公司 | 2021-06-15 | — | — | CN | disclosed |
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | GILEAD SCIENCES, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | ITGB7, ITGB4, ITGA4 | ITGB1 4/4885ITGA4 3/4885ITGB7 1/4885 |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | ITGB7, ITGB4, ITGA4 | ITGB1 4/4885ITGA4 3/4885ITGB7 1/4885 |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | ITGB1 4/4885ITGA4 3/4885ITGB7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.